Is hemolysis a novel therapeutic target in COVID-19?

• Daiki Ousaka,
• Masahiro Nishibori

Affiliations

Daiki Ousaka

Department of Pharmacology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan

Masahiro Nishibori

Translational Research and Drug Development, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan